Table 2.

Association of antibodies and risk of ASD, distribution and crude odds ratios, EMA study, births 2000–2001.

	N at MDL	Category	Analyte	ASD	Controls	ORunadj	95% CI
MATERNAL
Total IgG (μg/ml)		Q4	>53.63	18	36	0.77	(0.36, 1.66)
		Q3	>46.59–53.63	28	37	1.17	(0.57, 2.37)
		Q2	>43.11–46.59	14	37	0.58	(0.26, 1.30)
	0	(Ref*) Q1	0–43.11	24	37
Total IgM (μg/ml)		Q4	>65.96	15	35	0.55	(0.25, 1.19)
		Q3	>56.80–65.96	18	38	0.60	(0.29, 1.27)
		Q2	>29.56–56.80	22	37	0.76	(0.37, 1.56)
	0	(Ref*) Q1	0–29.56	29	37
Toxo IgG (SI)		Cat 4	>18.6	8	37	0.23	(0.09, 0.55)
		Cat 3	>6.3–18.6	15	35	0.45	(0.21, 0.96)
		Cat 2	>0–6.3	23	35	0.69	(0.35, 1.38)
	78	(Ref**) Cat 1	0	38	40
Toxo IgM (odu***)		Q4	>0.202	15	35	0.57	(0.26, 1.23)
		Q3	>0.172–0.202	22	38	0.77	(0.38, 1.56)
		Q2	>0.158–0.172	17	34	0.67	(0.32, 1.41)
	0	(Ref*) Q1	0–0.158	30	40
NEWBORN
Total IgG (μg/ml)		Q4	>61.18	18	38	0.66	(0.31, 1.38)
		Q3	>55.03–61.18	16	38	0.59	(0.27, 1.25)
		Q2	>51.63–55.03	18	38	0.66	(0.31, 1.38)
	0	(Ref*) Q1	0–51.63	28	39
Total IgM (μg/ml)		Cat2	>1.20	29	66	0.75	(0.43, 1.31)
	0	(Ref**) Cat 1	0–1.20	51	87
Toxo IgG (odu***)		Q4	>0.097	5	38	0.14	(0.05, 0.39)
		Q3	>0.066–0.097	23	38	0.64	(0.32, 1.27)
		Q2	>0.057–0.066	15	38	0.42	(0.20, 0.88)
	0	(Ref*) Q1	0–0.057	37	39

^*Reference quartile (Q1) includes signals at and above the MDL based on control values.

^**Reference category (Cat 1) only includes signals at the MDL. Values above the MDL divided into equal-sized categories based on control values.

^***Optical density units (blank adjusted).

Bold means statistically significant.